Skip to content
Clinical Trials – home

Fejer Varmegyei Szent Gyoergy Egyetemi Oktato Korhaz

Research site

Hungary Seregelyesi Ut 3, 8000 Szekesfehervar, Hungary

  • 31 trials recruiting
  • Non-small cell lung cancer · Colitis ulcerative · Psoriatic arthropathy
  • Adults and children

About Specializations

Fejer Varmegyei Szent Gyoergy Egyetemi Oktato Korhaz in Szekesfehervar, Hungary specialises in clinical trials of conditions such as Non-small cell lung cancer, Colitis ulcerative, Psoriatic arthropathy, Crohn's disease, and other specialisations. This site conducts important research.

Main research areas of the site

Rheumatology and Immunology

The medical center is at the forefront of research in rheumatology and immunology, focusing on innovative treatments for conditions such as Axial Spondyloarthritis and Psoriatic Arthritis. The center's work in these areas aims to improve long-term safety and efficacy of novel therapeutic agents.

  • Axial Spondyloarthritis
  • Psoriatic Arthritis

Through extensive clinical trials, the center is contributing to the development of new therapies that enhance patient outcomes and quality of life.

Gastroenterology

Specializing in gastroenterology, the center conducts pivotal studies on Ulcerative Colitis and Crohn's Disease. These studies focus on assessing the efficacy and safety of emerging treatments, aiming to induce clinical remission and improve endoscopic response.

  • Ulcerative Colitis
  • Crohn's Disease

The center's research is instrumental in advancing therapeutic strategies that address the complex needs of patients with inflammatory bowel diseases.

Oncology

The center is a leader in oncology research, with a focus on lung cancer and hematological malignancies. It explores novel treatment combinations and evaluates their impact on survival and disease progression.

  • Non-Small Cell Lung Cancer
  • Small Cell Lung Cancer
  • Chronic Lymphocytic Leukemia

By pioneering clinical trials, the center is enhancing the understanding of cancer biology and improving therapeutic options for patients worldwide.

Cardiology

In the field of cardiology, the center is dedicated to advancing treatments for Chronic Heart Failure and Myocardial Infarction. Research efforts focus on evaluating the efficacy of novel pharmacological interventions to improve cardiovascular outcomes.

  • Chronic Heart Failure
  • Myocardial Infarction

The center's contributions are pivotal in shaping future therapeutic approaches and enhancing patient care in cardiovascular medicine.

Nephrology

With a strong emphasis on nephrology, the center investigates innovative treatments for Sepsis-associated Acute Kidney Injury. The research aims to improve renal function and patient outcomes through novel therapeutic strategies.

  • Sepsis-associated Acute Kidney Injury

The center's work is crucial in developing effective interventions for kidney-related complications in critically ill patients.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Seregelyesi Ut 38000 SzekesfehervarHungary
Recruiting now
31 trials
Conditions studied
60

More sites in SzekesfehervarHungary

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

84 clinical trials

Cardiac failure

Recruiting

Study of maridebart cafraglutide for patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Long‑Term Safety and Efficacy of SPY001-001, SPY002 and SPY003 in Adults with Ulcerative Colitis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:SPY002
  • Sponsor:Spyre Therapeutics Inc.

Long-Term Safety and Efficacy of Zasocitinib in Adults with Active Psoriatic Arthritis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib
  • Sponsor:Takeda Development Center Americas Inc.

Phase III Randomized Study of Rilvegostomig vs. Pembrolizumab with Platinum-based Chemotherapy in PD-L1 Expressing Metastatic Squamous NSCLC

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

A Study of Long-acting Antibodies SPY001-001 and SPY002 Alone and Combined for Adults with Moderate to Severe Ulcerative Colitis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:SPY002
  • Sponsor:Spyre Therapeutics Inc.

Study of Zasocitinib and Apremilast for Adults with Active Psoriatic Arthritis Who Have Not Used Biologic Medicines

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Apremilast
  • Sponsor:Takeda Development Center Americas Inc.

Crohn's disease

Recruiting

Study of RO7790121 (afimkibart) for Treatment and Long-term Management in Adults with Moderate to Severe Crohn's Disease

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:RO7790121
  • Sponsor:F. Hoffmann-La Roche AG

Crohn's disease

Recruiting

Study on the Effectiveness and Safety of Obefazimod for Patients with Moderate to Severe Crohn's Disease After Inadequate Response to Other Treatments

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Study on Eltrekibart and Mirikizumab for Adults with Moderate to Severe Ulcerative Colitis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Mirikizumab
  • Sponsor:Eli Lilly & Co.

Study comparing rilvegostomig plus chemotherapy versus pembrolizumab plus chemotherapy for first-line treatment in patients with metastatic non-squamous lung cancer with PD-L1 expression

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Crohn's disease

Recruiting

Study on the Effects of MORF-057 for Adults with Moderate to Severe Crohn's Disease

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:MORF-057
  • Sponsor:Morphic Therapeutic Inc.

Study on the Long-term Safety and Efficacy of Pembrolizumab and Lenvatinib for Patients with Advanced Tumors

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.